Clinical Trials Browser

OTHER × Ipilimumab × Head & Neck × Clear all

NCT04080804 2026-04-22

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03799445 2026-03-17

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Phase 2 Active not recruiting

37 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02919683 2026-01-28

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Phase 2 Active not recruiting

30 enrolled 14 charts

Head and Neck Neoplasms

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase 2 Completed

20 enrolled 13 charts

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03172624 2025-12-18

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Phase 2 Completed

64 enrolled 9 charts

Salivary Gland Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03449108 2025-11-21

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Phase 2 Active not recruiting

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03690986 2025-07-23

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03246958 2025-06-19

Nivolumab Plus Ipilimumab in Thyroid Cancer

Phase 2 Completed

53 enrolled 19 charts

Thyroid Neoplasms

NCT03406247 2025-05-08

ADJORL1

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03162731 2025-04-29

Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

Phase EARLY_PHASE1 Completed

Lymphoid Interstitial Pneumonia, Laryngeal Diseases

NCT02812524 2025-03-10

Ipilimumab for Head and Neck Cancer Patients

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03146650 2024-01-18

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Phase 2 Unknown

25 enrolled 14 charts

Salivary Gland Neoplasms

NCT03749460 2023-12-29

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Phase 1/2 Completed

20 enrolled 12 charts

Salivary Gland Neoplasms

NCT03003637 2023-10-23

IMCISION

Phase 1/2 Completed

Head and Neck Neoplasms

NCT03097939 2023-10-11

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT03700905 2023-05-23

IMSTAR-HN

Phase 3 Unknown

Head and Neck Neoplasms

NCT03620123 2022-11-18

OPTIM

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Recurrence